Overall survival (OS) in BRCA -mutated breast cancer improved significantly with the addition of olaparib (Lynparza) to ...

Today, Pfizer said that its phase 3 TALAPRO 2 trial of PARP drug Talzenna (talazoparib) in combination with its Astellas-partnered anti-androgen therapy Xtandi (enzalutamide) reduced radiographic ...

BARD1 mutations, also seen in some breast cancers, can respond to a class of drugs called poly(ADP-ribose) polymerase (PARP) inhibitors, which interrupt the DNA repair process of cancer cells.

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Figure 1: Domain architecture of the classic poly-ADP-ribose-polymerase PARP1 and the newly characterized mono-ADP-ribosyltransferase PARP10. Figure 2: Classification of the poly-ADP-ribose ...